Lincolnshire Prescribing and Clinical Effectiveness Forum (PACEF) was founded in 2007. It is the current strategic advisory network to NHS Lincolnshire CCG. PACEF has the responsibility for ensuring the cost-effective use of medicines and other healthcare interventions and their functional integration into healthcare delivery across Lincolnshire.

Representation on the group is comprised of leading professionals from the Lincolnshire Clinical Commissioning Group, primary care, the local Acute Trusts (United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust), Lincolnshire Community Health Services, Local Medical Council and Local Pharmaceutical Council. 

PACEF Bulletins

Title
PACE Bulletin Vol 14 No 5 Nov20

Description

DRUG ASSESSMENT SUMMARY:

Vigabatrin soluble tablets approved as AMBER 2.

Fentany Lozenge – Cynril not approved RED/RED.

Suliqua Insulin glargine/lixisenatide 100units/33mcg/ml and 100units/50mcg/ml pre-filled pens approved as GREEN.

Tolterodine prolonged release capsules (Blerone XL approved as GREEN.

Dalonev ((50mcg calcipotriol & 0.5mg betamethsone per g) ointment approved as GREEN.

FORMULARY UPDATES:

Glucogel

Abidec

PACE Bulletin Vol 14 No 4 Jul20

Description

Drug Assessment Summary.

Leuprorelin acetate 3.75mg (Prostap SR DCS) and 11.5mg (Prostap 3 DCS). Licence extended to cover treatment of breast cancer. Approved as AMBER 2.

Triptorelin SR 3mg license extended to cover treatment of breast cancer. Approved as AMBER 2.

Timolol 0.5% Long Acting gel (Timoptol LA 0.5% Gel). Approved As AMBER 2 for unlicensed use for the management of infantile haemangioma.

PACE Bulletin Vol 14 No 3 Mar20

Description

Drug Assessment Summary.

Sildenafil 25mg & 50mg tablets unlicensed use for treatment of severe Raynaud Syndrome unresponsive to first-line treatments. Approved as AMBER 2.

InVita D3® – 800units Colecalciferol soft capsules for treatment of vitamin D deficiency. Approved as AMBER 2.

Octasa 1600mg modified release mesalazine tablets used for treatment of mild to moderate acute ulcerative colitis. Approved as AMBER 2.

Xaggitin XL® (methylphenidate hydrochloride) prolonged-release tablets prolonged-release tablets 18mg, 27mg, 36mg or 54mg. Used for the treatment of ADHD in children and adolescents. Approved as AMBER 1.

Acetylcysteine 5% with Hypromellose 0.35% (Ilube®) eye drops. Approved as AMBER 2 for the treatment of corneal filaments.

PACE Bulletin Vol 14 No 2 Jan20 Items Which Should Not Be Routinely Prescribed in Primary Care

Description

Summary of NHS England guidance on items which should not be routinely prescribing in primary care

PACE Bulletin Vol 14 No 1 Jan20

Description

Drug Assessment Summary.

Budnesonide orodispersible tablets 1mg tablets (Jorveza®) approved as AMBER 2 for treatment of eosinophilic oesophagitis.

Fixapost® preservative free combination eye drops containing latanoprost and timolol licensed for reduction of intraocular pressure. Approved as AMBER 2.

Ketotifen (tablets or liquid) off-label use for the treatment of mast cell activation disease. Approved as AMBER 2.

Alimemazine re-classed from GREEN to AMBER 2 for the management of sleep disorders in children with neurodevelopmental disorders, who have failed to respond to treatment with melatonin.

DesmoMelts® – oral lyophillisate desmopressin approved as GREEN for treatment of primary nocturnal enuresis.